YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
暂无分享,去创建一个
Akira Iizuka | Masaru Komiyama | Koichi Mitsuya | T. Ashizawa | A. Iizuka | H. Miyata | T. Sugino | K. Yamaguchi | Y. Akiyama | Masaru Komiyama | Y. Nakasu | Chie Oshita | Nakamasa Hayashi | Yasuto Akiyama | Ken Yamaguchi | Tadashi Ashizawa | Haruo Miyata | Chie Oshita | Maho Omiya | Akiko Kume | Takashi Sugino | Yoko Nakasu | K. Mitsuya | A. Kume | N. Hayashi | Maho Omiya
[1] R. Ramesh,et al. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells , 2008, Molecular Cancer Therapeutics.
[2] L. Deangelis,et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. , 2011, Neuro-oncology.
[3] T. Ashizawa,et al. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. , 2013, International journal of oncology.
[4] Bruce Mickey,et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. , 2009, Cancer research.
[5] C. Bokemeyer,et al. Elevated pretreatment serum concentration of YKL‐40—An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer , 2010, Cancer.
[6] Mark R Gilbert,et al. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. , 2002, Cancer research.
[7] R. Shao,et al. Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma* , 2011, The Journal of Biological Chemistry.
[8] E. Domany,et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Tracy T Batchelor,et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.
[10] T. Tamiya,et al. Association between YKL‐40 and adult primary astrocytoma , 2010, Cancer.
[11] Yuan Qi,et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .
[12] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[13] S. Goerdt,et al. Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer , 2007, Biomarker insights.
[14] P. Day,et al. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. , 2013, Neuro-oncology.
[15] P. Vlachostergios,et al. Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner , 2013, Investigational New Drugs.
[16] R. Scienza,et al. Serum YKL-40 following resection for cerebral glioblastoma , 2012, Journal of Neuro-Oncology.
[17] S. Kjaer,et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. , 2003, Oncology reports.
[18] Katarzyna M. Wilczynska,et al. A Complex of Nuclear Factor I-X3 and STAT3 Regulates Astrocyte and Glioma Migration through the Secreted Glycoprotein YKL-40* , 2011, The Journal of Biological Chemistry.
[19] R. Shao,et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis , 2009, Oncogene.
[20] R. McLendon,et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Wei Keat Lim,et al. The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.
[22] A. Balmain,et al. Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.
[23] Junnian Zheng,et al. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. , 2011, Biochemical and biophysical research communications.
[24] S. Kohsaka,et al. STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression , 2012, Molecular Cancer Therapeutics.
[25] Karen H. Almeida,et al. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. , 2005, Cancer research.
[26] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[27] Koji Yoshimoto,et al. Primary Glioblastomas Express Mesenchymal Stem-Like Properties , 2006, Molecular Cancer Research.
[28] R. Mirimanoff,et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] I. Germano,et al. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide , 2003, British Journal of Cancer.
[30] Allan H Friedman,et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] L. Deangelis,et al. YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas , 2006, Clinical Cancer Research.
[32] J. Sarkaria,et al. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance , 2010, Journal of Neuro-Oncology.
[33] T. Ashizawa,et al. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. , 2011, International journal of oncology.
[34] A. Verma. MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .